Evidence map›Paper›PMID 41188912›Full record

ArticleJournal of translational medicine2025

Gut microbiota-derived arginine metabolism mitigates intestinal ischemia-reperfusion injury.

Xiaoxi Li, Min Hou, Jipeng Lyu, Xiangzhen Min, Xiaoxia Han, Xinrun Wang, Zhenzhen Liu, Yufang Leng

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoxi LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Min HouThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Jipeng LyuThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Xiangzhen MinThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Xiaoxia HanThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Xinrun WangThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Zhenzhen LiuDepartment of Anaesthesiology, Peking University First Hospital, Beijing, 100034, China. liuzhzh@bjmu.edu.cn.
Yufang LengThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China. lengyf@lzu.edu.cn.

Funding

Natural Science Foundation of china 82260381
6 · The paper itself

Abstract

backgroundIntestinal ischemia-reperfusion (I/R) injury is a severe pathological condition characterized by disruption of the mucosal barrier, immune dysregulation, and gut microbiota imbalance. However, whether the gut microbiota regulates immune homeostasis and mucosal repair through arginine metabolism remains unclear.

methodsWe employed antibiotic-treated and fecal microbiota transplantation (FMT) mouse models, MNK-3 cells, metabolomics, arginine supplementation, and CASTOR1 knockout mice to evaluate intestinal barrier integrity, inflammatory responses, and signaling pathways following I/R injury.

resultsI/R injury induced significant microbial dysbiosis and decreased fecal arginine levels. FMT demonstrated that microbial alterations reshaped arginine metabolism in recipient mice. Arginine supplementation restored tight junction protein expression, downregulated pro-inflammatory cytokines, enhanced interleukin (IL)-22 secretion, and suppressed IL-17 upregulation. Mechanistically, arginine activated mTORC1 signaling via CASTOR1, thereby promoting IL-22 production, whereas CASTOR1 deficiency or mTORC1 inhibition markedly impaired its protective effects.

conclusionsThe gut microbiota functions as an upstream regulator of arginine metabolism during I/R injury. Arginine confers immunoprotection by activating the CASTOR1–mTORC1–ILC3 axis, enhancing cytokine secretion and promoting mucosal repair. These findings reveal a novel microbiota–metabolism–immunity interplay and suggest nutrient-sensing pathways as promising therapeutic targets in intestinal injury.

Indexed as

ArginineGastrointestinal MicrobiomeIntestinesReperfusion InjuryAnimalsCytokinesFecal Microbiota TransplantationInterleukin-22InterleukinsIntestinal Barrier FunctionIntestinal MucosaMaleMechanistic Target of Rapamycin Complex 1Mice, Inbred C57BLMice, KnockoutSignal TransductionArginineCytokinesInterleukin-22InterleukinsMechanistic Target of Rapamycin Complex 1Arginine metabolismCASTOR1Fecal microbiota transplantationGut microbiotaIschemia-reperfusion injurymTORC1

Identifiers

PMID41188912
PMCPMC12584287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.